Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for April 26, 2022

4/26/2022

 
Regulatory Update
 
The FDA granted Fast Track status to ADI-001 for the treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphoma.
 
PLOS One has retracted five articles describing research evaluating simufilam for the treatment of Alzheimer’s disease (AD). According to the New York Times (NYT), the studies were retracted due to questions regarding the validity of the results. NYT interviewed nine AD expert and all expressed concern over the design of the trials and the accuracy of the results.
 
The FDA accepted the NDA for daprodustat for the treatment of anemia of chronic kidney disease (CKD) and assigned a PDUFA date for 2/1/2023
 
The FDA accepted the resubmitted BLA for daxibotulinumtoxinA for the treatment of moderate to severe glabellar lines and set a PDUFA date for 9/8/2022.
 
The FDA accepted the BLA for tremelimumab, given with durvalumab, for the treatment of unresectable hepatocellular carcinoma suggesting a PDUFA date for 10/25/2022.
 
CHMP recommended approval of mosunetuzumab for the treatment of relapsed or refractory follicular lymphoma after failure of at least two prior systemic therapies.
 
Announced Research Updates
 
Mirati announced results from a Phase I/II trial, evaluating the combination of sitravatinib plus nivolumab in the treatment of advanced clear cell renal cell cancer. 
 
Published Research Updates
 
Results were published from a Phase II trial evaluating the outcome from adding cilofexor and/or firsocostat to semaglutide in patients with NASH.
 
The Phase III, Chinese RATIONALE 302 trial results were published describing a comparison of treatment with tislelizumab to investigator’s choice of paclitaxel, docetaxel or irinotecan (in the treatment of advanced or metastatic esophageal squamous cell carcinoma.
 
Results from a Phase II trial were published evaluating pixantrone in the treatment of refractory HER2-negative metastatic breast cancer.
 
The SURPASS-3 CGM sub-study results were published, comparing tirzepatide to insulin degludec, for maintainingblood glucose in the target range of 71-140 mg/dL in patients with type 2 diabetes.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.